Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03322059
Other study ID # RSCA111
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2017
Est. completion date December 1, 2018

Study information

Verified date July 2019
Source California Polytechnic State University-San Luis Obispo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators propose to examine whether linking daily activity with charity-based incentives motivates cancer survivors to initiate and maintain physical activity. Linking daily physical activity goals with a cancer specific charity incentive may provide a uniquely salient motivator that promotes increased physical activity among cancer survivors. The investigators will examine whether using activity monitors in combination with charitable incentives leads to greater increases in physical activity compared to activity monitors alone. Target participants includes cancer survivors who are not already active. Physical activity (e.g., steps per day, time in moderate-intensity activity) will be examined at baseline and following a 12-week intervention period using an activPAL accelerometer. After the baseline assessment, both groups will receive a fitbit monitor and informational material designed to increase physical activity. Participants in the fitbit+charity group will have donations made in their name to a cancer charity if they meet daily step goals. Physical activity levels will be monitored using the fitbit device for 6-weeks following the formal intervention period.


Description:

The study is a Randomized Controlled Trial (RCT) of a 12-week physical activity intervention. Fifty cancer survivors will be recruited and allocated to one of two research arms: Fitbit+Only Group or Fitbit+Charity Incentives Group. Participants in both intervention arms will be asked to track their physical activities using Fitbit One, an activity monitor that monitors steps and physical activity and will receive basic educational materials about increasing physical activity. Those in the Fitbit+charity incentives Group will raise money for cancer charities if they meet weekly step targets.

The key outcome variable of the RCT is steps as measured by an activPAL accelerometer. Data will be collected at baseline and 12-weeks. Fitbit data will also be collected for the duration of the 12-week intervention and for 6-weeks following the end of the intervention period to have an initial examination of behavior change maintenance (total 18-weeks).


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date December 1, 2018
Est. primary completion date December 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Adults = 18 years and <50 y, with diagnosed Adolescent or Young Adult cancer (diagnosed between 15-39y of age);

2. = 6 months post-cancer treatment

3. English speaking

4. Participate in <60 minutes of MVPA/week

5. Own a smartphone

6. Have access to computer

7. Participants must also pass a physical activity readiness questionnaire or receive medical clearance from their primary care physician or oncologist.

Exclusion Criteria:

1. Joint, cardiovascular, or respiratory problem(s) precluding physical activity

2. Metastatic disease

3. Planned elective surgery or pregnancy during intervention/follow-up that would interfere with participation (e.g., breast reconstructive surgery).

4. Already using a wearable device >5 days per week

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Experimental
Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
Control
Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).

Locations

Country Name City State
United States California Polytechnic State University San Luis Obispo California

Sponsors (1)

Lead Sponsor Collaborator
California Polytechnic State University-San Luis Obispo

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Daily steps Daily steps as measured by activPAL 12 weeks - change from baseline to 12 weeks
Secondary Participant retention Proportion of participants retained of those randomized 12 weeks
Secondary Intervention Reach Proportion of individuals who agree to participate of those who express an interest in participation Baseline
Secondary Step goal adherence Proportion of weeks meeting physical activity goal as measured by fitbit 1-12 weeks
Secondary Daily Steps Daily Steps as Measured by Fitbit baseline to 12 weeks
Secondary Sleep Sleep as Measured by Fitbit baseline to 12 weeks
Secondary Sedentary time Sedentary time as Measured by activPAL activity monitor Change from baseline to 12 weeks
Secondary Standing time Standing time as Measured by activPAL Change from baseline to 12 weeks
Secondary Stepping time Stepping time as Measured by activPAL Change from baseline to 12 weeks
Secondary Moderate-vigorous intensity physical activity (MVPA) time MVPA time as Measured by activPAL Change from baseline to 12 weeks
Secondary Sedentary breaks/patterns Sedentary breaks/patterns as Measured by activPAL Change from baseline to 12 weeks
Secondary Fatigue Patient-Reported Outcomes Measurement Information System Fatigue Short Form 8a (Total Score range 8-40). higher score is more fatigue. Change from baseline to 12 weeks
Secondary Physical Function Patient-Reported Outcomes Measurement Information System Physical Function Short Form 20a. Total score (range 20-100). Higher score is worse physical function Change from baseline to 12 weeks
Secondary Depression Patient-Reported Outcomes Measurement Information System Depression Short Form 8a. Total score range 8-40. Higher score is more depressed. Change from baseline to 12 weeks
Secondary Attitudes Toward Charitable Giving Attitudes Toward Charitable Giving Scale. Total of 20 questions with scores from 1-5, there are five domains higher score is more of a particular attitude. 1.) Inefficiency of Charitable Giving 2.) Efficiency of Charitable Giving 3.) Cynical Giving 4.) Altruistic Giving 5.) Purpose of Charity Change from baseline to 12 weeks
Secondary Behavioral Regulation in Exercise Questionnaire Behavioral Regulation in Exercise Questionnaire -3. Contains 6 subscales Amotivation, external regulation, introjected regulation, identified regulation, integrated regulation, intrinsic regulation, each range from 0-16, higher values indicate more motivation in that domain. Change from baseline to 12 weeks
Secondary Barriers Self-efficacy Scale Barriers Self-efficacy Scale. 15 items, total score range 0-1500. Higher indicated more self-efficacy Change from baseline to 12 weeks
Secondary Physical Activity Enjoyment Physical Activity Enjoyment Scale. 18-item scale with 7-point bipolar rating. Total score range 18-126. Higher scores reflect greater levels of enjoyment. Change from baseline to 12 weeks
Secondary Pittsburg Sleep Quality Questionnaire Pittsburg Sleep Quality Questionnaire. Total score. Greater than 5 indicated poor sleep quality. Change from baseline to 12 weeks
Secondary Exercise Self-efficacy Scale Exercise Self-efficacy Scale. 6 items total score. Range 0-600, higher is more self-efficacy Change from baseline to 12 weeks
Secondary Intervention Maintenance % of weeks adhered to step goal as measured by fitbit during 6-week follow-up period 12-18 weeks
Secondary Duration wore Fitbit Duration wore Fitbit during during 6-week follow-up period 12-18 weeks
Secondary Exercise outcome expectations Multidimensional Outcome Expectations for Exercise Scale. Total score (range 15-75), higher score means more multidimensional outcome expectations. Change from baseline to 12 weeks
Secondary Sleep disturbance Patient-Reported Outcomes Measurement Information System Sleep Disturbance Form. Total score range 8-40. Higher score is more disturbance. Change from baseline to 12 weeks
Secondary Exercise Goal Setting 10-item total score. Ranged from 10 to 50, higher score means more goal setting. Exercise Goal-Setting Scale. Change from baseline to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases